alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 51–75 of 360 studies published 2015 · free to read (page 3 of 15) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of these 360 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Neurology 2015-07-24

The (11)C-PiB-PET imaging results demonstrated reduction of fibrillar Aβ accumulation in patients with Alzheimer disease treated with bapineuzumab; however, as no clinical benefit was observed, the findings are consistent with the hypotheses that bapineuzumab may not have been initiated early enough in the disease course, the doses were insufficient, or the most critical Aβ species were inadequately targeted. 4 key findings →

Design: clinical trial Participants: 115 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Brain : a journal of neurology 2015-03-23

Second, we examined the relevance of Thal amyloid phase in a prospectively-followed autopsied cohort who underwent ante-mortem (11)C-Pittsburgh compound B imaging; using the large autopsy cohort to broaden our perspective of (11)C-Pittsburgh compound B results. 2 key findings →

Participants: 3,618 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2015-03-05

Reference region selection has an important influence on the detection of florbetapir change. 4 key findings →

Design: longitudinal study Participants: 14 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA psychiatry 2015-03-01

Although the presence of abnormal levels of amyloid-β (Aβ) is associated with higher rates of progression to clinically classified mild cognitive impairment or dementia, little research has evaluated potentially modifiable moderators of Aβ-related cognitive decline, such as anxiety and depressive symptoms. 5 key findings →

Design: cohort study Participants: 333 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults

✓ Peer-reviewed alzhub usefulness score 65 out of 100. BMC geriatrics 2015-09-07

MoCA and MMSE were more similar for dementia cases, but MoCA distributes MCI cases across a broader score range with less ceiling effect. 4 key findings →

Design: cross-sectional Participants: 219 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mixed pathology is more likely in black than white decedents with Alzheimer dementia

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Neurology 2015-07-15

Black decedents with AD dementia are more likely to have mixed brain pathologies compared with age-, sex-, education-, and cognition-matched white decedents with AD dementia. 2 key findings →

Design: cohort study Participants: 122 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Diabetes care 2015-01-15

Older adults with diabetes and dementia are at increased risk for hypoglycemia and other adverse events associated with tight glycemic control and are unlikely to experience long-term benefits. 4 key findings →

Design: cohort study Participants: 15,880 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA neurology 2015-08-01

The best cluster solution found was based on orthostatic hypotension, mild cognitive impairment, rapid eye movement sleep behavior disorder (RBD), depression, anxiety, and Unified Parkinson's Disease Rating Scale Part II and Part III scores at baseline. 1 key finding →

Design: cohort study Participants: 113 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA neurology 2015-11-01

Baseline CSF levels of NGRN in patients with AD (median level, 2381 pg/mL [interquartile range, 1651-3416 pg/mL]) were higher than in cognitively normal participants (median level, 1712 pg/mL [interquartile range, 1206-2724 pg/mL]) (P = .04). 3 key findings →

Design: longitudinal study Participants: 163 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Low cardiac index is associated with incident dementia and Alzheimer disease: the Framingham Heart Study

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Circulation 2015-02-19

Cross-sectional epidemiological and clinical research suggests that lower cardiac index is associated with abnormal brain aging, including smaller brain volumes, increased white matter hyperintensities, and worse cognitive performances. 4 key findings →

Design: cross-sectional Participants: 184 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Multidomain Lifestyle Interventions for the Prevention of Cognitive Decline After Ischemic Stroke: Randomized Trial

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Stroke 2015-09-15

This trial found no benefit of 24-month multidomain intervention with focus on improvement in lifestyle and vascular risk factors on the incidence of poststroke cognitive decline in comparison with standard stroke care. 1 key finding →

Participants: 101 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Movement disorders : official journal of the Movement Disorder Society 2015-04-16

Substantial variability occurs in the prevalence of "PiB-positive" studies in subjects with Parkinsonism and cognitive impairment. 2 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs

✓ Peer-reviewed alzhub usefulness score 64 out of 100. JAMA internal medicine 2015-04-01

Low daytime SBP was independently associated with a greater progression of cognitive decline in older patients with dementia and MCI among those treated with AHDs. 5 key findings →

Design: cohort study Participants: 172 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Integrated genomic approaches identify major pathways and upstream regulators in late onset Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Scientific reports 2015-07-23

Previous studies have evaluated gene expression in Alzheimer's disease (AD) brains to identify mechanistic processes, but have been limited by the size of the datasets studied. 4 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span

✓ Peer-reviewed alzhub usefulness score 63 out of 100. JAMA neurology 2015-05-01

Overall, memory worsened from age 30 years through the 90s. The HVa worsened gradually from age 30 years to the mid-60s and more steeply beyond that age. 5 key findings →

Design: cross-sectional Participants: 1,246 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Circulation 2015-04-10

By conditioning on the genetic association with the cardiovascular phenotypes, we identify novel AD susceptibility loci, including 2 genome-wide significant variants conferring increased risk for AD. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed